These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 24333977)

  • 1. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
    Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
    Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
    Ayez N; van der Stok EP; Grünhagen DJ; Rothbarth J; van Meerten E; Eggermont AM; Verhoef C
    Eur J Surg Oncol; 2015 Jul; 41(7):859-67. PubMed ID: 25979624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
    Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
    Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
    Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
    Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
    J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
    Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
    Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
    Tanaka K; Nojiri K; Kumamoto T; Takeda K; Endo I
    Eur J Surg Oncol; 2011 Apr; 37(4):336-43. PubMed ID: 21277151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
    Jakab F
    Orv Hetil; 2010 Nov; 151(47):1956-60. PubMed ID: 21071308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Liver resection after downstaging with neoadjuvant chemotherapy for "unresectable" colorectal metastases].
    Frena A; Martin F; La Guardia G; Vezzali N; Bonatti G; Stocker J; Graiff C
    Chir Ital; 2004; 56(3):351-7. PubMed ID: 15287631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
    Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
    HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
    Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
    Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
    J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
    Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
    Krieger PM; Tamandl D; Herberger B; Faybik P; Fleischmann E; Maresch J; Gruenberger T
    Ann Surg Oncol; 2011 Jun; 18(6):1644-50. PubMed ID: 21207168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
    Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
    Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.